secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001493152-23-006509
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic CMO Fatih Uckun resigns; CRO Seymour Fein assumes CMO role
--------------------------------------------------------------------

- Fatih Uckun, MD, PhD, resigned as Chief Medical Officer effective February 28, 2023.
- Seymour Fein, MD, currently Chief Regulatory Officer, will take over as CMO.
- Fein will continue as CRO while assuming additional CMO responsibilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315223006509/0001493152-23-006509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315223006509/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-006509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer